Lifestyle
New Weight-Loss Injection Delivers 20% Weight Reduction
A weekly injection that combines two medicines helped adults lose around one-fifth of their body weight in a major clinical trial. The findings suggest that even lower doses of the combination could offer meaningful weight loss.
The experimental treatment, called CagriSema, brings together semaglutide and cagrilintide. Both act on the body’s signals for hunger and fullness, although they work in different ways. The goal is to help people feel satisfied with less food.
Obesity is more than a question of appearance. It can raise the risk of high blood pressure, heart disease and breathing problems during sleep. Losing weight can improve some of these health problems, but keeping weight off is often difficult.
The new study, called REDEFINE 9, was published in The Lancet Diabetes & Endocrinology in November 2026. Researchers followed 309 adults for 68 weeks at 24 medical centers across five countries. All had obesity, or were overweight with a related health condition, and none had diabetes.
Participants were randomly assigned to one of three groups. Two groups received different lower doses of CagriSema, while the third received an injection without active medicine. Everyone also received advice about food and physical activity.
Among people who stayed on treatment, the average weight loss was 20.7% in the higher-dose group and 21.0% in the lower-dose group. The comparison group lost 2.0% on average. When researchers counted everyone, including those who stopped treatment, the average losses were 19.4%, 18.6% and 4.6%.
About half of those taking CagriSema lost at least 20% of their starting weight. Their waist measurements also fell by roughly 17 centimeters, compared with about 4 centimeters in the comparison group.
The similar results from both doses are encouraging. They raise the possibility that doctors might one day choose among doses based on patients’ needs rather than assuming more medicine always produces better results.
However, this was a relatively small study, and its participants were mostly women. It did not establish how well the treatment works for everyone or what happens after many years. CagriSema remains an investigational treatment, so larger and longer studies are needed before firm conclusions can be drawn.
-
BREAKING NEWS2 months agoOgun Residents Raise Questions Over Yayi’s Campaign Spending
-
SPORTS1 month agoPremier League Referees Admit “Error of Judgement” Over Haaland Goal Against Man United
-
BREAKING NEWS4 months agoJUST-IN: 28-Year-Old Nigerian Man Deported From Ireland After Conviction for T£rror Offences and Mass M¥rder Threats in UK
-
BREAKING NEWS4 months agoOyo Police Bust Alleged Railway Vandalism Syndicate, Recover Stolen Rail Tracks Worth ₦200 Million
-
BREAKING NEWS4 months agoHow Woman Arrested for Br¥talising 13-Year-Old Domestic Worker in Imo state
-
SPORTS2 months agoBREAKING: Jorge Jesus Speaks on Cristiano Ronaldo Situation Ahead of Dragão Clash
-
BREAKING NEWS3 weeks agoBREAKING: Adamawa Police Arrest Three Kidnap Suspects, Recover Two Ak-47 Rifles, ₦5.52million
-
Health5 hours agoNew Sleep Apnea Treatment Improves Breathing for Patients, See More
